Outcomes for patients referred urgently with suspected head and neck cancer

2008 ◽  
Vol 122 (11) ◽  
pp. 1241-1244 ◽  
Author(s):  
J C Hobson ◽  
J V Malla ◽  
J Sinha ◽  
N J Kay ◽  
L Ramamurthy

AbstractIntroduction:The 1998 National Health Service White Paper stated that anyone suspected of having a cancer would be seen by a specialist within two weeks. The ‘trigger symptoms’ prompting such referral have been nationally agreed by the National Institute for Health and Clinical Excellence. This study aimed to quantify the diagnostic yield of urgent referrals for suspected head and neck malignancy, and to identify reasons why patients ultimately diagnosed with malignancy may not have been referred via this pathway.Materials and methods:All patients referred to the trust with suspected head and neck malignancy in 2005 were included in the study. Data were obtained on date of referral, date of appointment, reason for referral and which National Institute for Health and Clinical Excellence guideline heading the referral fell under, clinical findings, and final diagnosis. Concurrently, all patients in the trust with a histological diagnosis of head and neck malignancy were identified using the computer records of the pathology department.Results:One hundred and seventy-seven patients were referred with suspected head and neck malignancy over the one-year study period. Of these, 169 were seen within two weeks. The commonest causes of referral were hoarseness and neck lumps. Of these patients, 22 (12 per cent) were ultimately diagnosed with malignancy. During the one-year study period, 39 patients were diagnosed hospital-wide with head and neck malignancy, 17 of whom had not been referred via the urgent referral pathway. No unifying theme was identified to explain why these patients had not been referred via this pathway.Conclusion:In a group of patients with symptoms suggestive of head and neck malignancy, only 12 per cent were ultimately diagnosed with cancer. Of all the patients within the trust diagnosed with head and neck cancer, 44 per cent had come from outside the urgent referral pathway.

ORL ◽  
2021 ◽  
pp. 1-3
Author(s):  
Jérôme R. Lechien ◽  
Daphné Delplace ◽  
Mohamad Khalife ◽  
Sven Saussez

Neutrophilic febrile dermatosis (NFD) is a rare paraneoplastic syndrome that may be found in patients with head and neck cancer. NFD may appear before the neoplasia and may only concern the dorsal faces of the hands. This article reports the NFD findings of a patient with pharyngeal cancer, which was developed 2 years after the occurrence of NFD. The development of NFD in patient with alcohol and tobacco consumption should lead otolaryngologists and dermatologists to suspect head and neck malignancy. In cases of normal otolaryngological examination, patients have to be followed.


2019 ◽  
Vol 101 (2) ◽  
pp. 103-106 ◽  
Author(s):  
CM Douglas ◽  
V Carswell ◽  
J Montgomery

Introduction Primary care patients with a suspected head and neck cancer are referred through the urgent suspicion of cancer referral pathway. Rates of cancer detection through this pathway are low. Evidence surrounding the pathway of these patients is lacking. This study aimed to determine the outcome of urgent suspicion of cancer referrals for head and neck cancer. Methods and methods All head and neck cancer urgent suspicion of cancer referrals in NHS Greater Glasgow and Clyde between June 2015 and May 2016 were analysed in regard to their clinical pathway. Results There were 2116 urgent suspicion of cancer referrals in the one-year period. The overall cancer rate was 235 (11.8%), compared with 152 (7.6%) that resulted in a primary head and neck cancer diagnosis. Of the total, 851 (42.6%) were reassured and discharged after one clinic appointment; 536 (26.8%) were followed up for suspected benign pathology and 436 (21.8%) were actively investigated for cancer. Conclusion A significant proportion of patients attending urgent suspicion of cancer clinic appointments can be seen and discharged in one clinic appointment, provided there is same day imaging available. Cancer identification rates through urgent suspicion of cancer pathways remain low.


1995 ◽  
Vol 112 (5) ◽  
pp. P185-P185
Author(s):  
Thomas M. Kidder

Educational objectives: To understand the rationale and need for the head and neck surgeon to provide continuing and terminal care for patients dying of incurable head and neck malignancy and to effectively and confidently relieve pain and manage other distressing symptoms afflicting patients with incurable head and neck cancer.


2012 ◽  
Vol 94 (3) ◽  
pp. 101-105 ◽  
Author(s):  
R Kumar ◽  
M Drinnan ◽  
H Mehanna ◽  
V Paleri

The publication of the NHS Cancer Plan by the Department of Health in September 2000 led to an increase in the number of urgent referral clinics as the guidelines stipulated that cancer patients should not wait more than two months from referral to initiation of treatment. 1 following the implementation of these guidelines for head and neck cancer (HNC) referrals in December 2000, the National Institute for Health and Clinical Excellence (NICE) released an update as part of Clinical Guidance 27 in 2005 2 outlining eight key symptoms that should prompt urgent referral to secondary care.


1995 ◽  
Vol 109 (11) ◽  
pp. 1072-1076 ◽  
Author(s):  
M. G. Dtlkes ◽  
M. L. DeJode ◽  
Q. Gardiner ◽  
G. S. Kenyon ◽  
P. McKelvie

AbstractPhotodynamic therapy (PDT) is a new and promising treatment modality for the treatment of malignant disease. This paper reports the preliminary experience of our group in the use of this therapy for the treatment of tumours arising in the head and neck. The majority of treatments in these cases have used a second generation systemic photosensitizer, meta-tetrahydroxyphenylchlorin (m-THPC). Two other cases were treated with either Photofrin 2 (a first generation systemic sensitizer) or with the topical photosensitizer, delta-aminolaevulinic acid (δ-ALA).The initial results have been encouraging with good clinical responses evident in patients presenting with a variety of differing tumour types. We feel there is now sufficient evidence of the efficacy of this treatment to warrant a multicentre prospective study into the treatment of early head and neck cancer with PDT.


Author(s):  
Natalia Muñoz Vigueras ◽  
Vanessa Gabriela Jerviz Guia ◽  
Isabel Castillo Pérez ◽  
Paula Obeso Benitez ◽  
Javier Martín Núñez ◽  
...  

2015 ◽  
Vol 191 (6) ◽  
pp. 501-510 ◽  
Author(s):  
Silke Tribius ◽  
Marieclaire Raguse ◽  
Christian Voigt ◽  
Adrian Münscher ◽  
Alexander Gröbe ◽  
...  

2017 ◽  
Vol 24 (7) ◽  
pp. 553-554 ◽  
Author(s):  
Matthew A Hoch ◽  
Kati Cousins ◽  
Ruth Nartey ◽  
Keith Riley ◽  
Megan Hartranft

Two patients diagnosed with advanced head and neck cancer were treated with cetuximab 400 mg/m2 intravenously for one loading dose followed by 250 mg/m2 IV on days 1, 8, and 15 along with paclitaxel 80 mg/m2 and cisplatin 30 mg/m2 intravenously on days 1 and 8 repeated every 21 days for three cycles (CPP). Maintenance cetuximab 250 mg/m2 intravenously weekly was continued following the aforementioned regimen for one year or until disease progression. Patient A was diagnosed with squamous cell carcinoma of the parotid gland treated initially with parotidectomy and radiation therapy. After the detection of multiple lung metastases, he received three cycles of CPP and maintained a stable disease after one year. Patient B was diagnosed with metastatic laryngeal cancer and was initially treated with three cycles of docetaxel, cisplatin, and continuous infusion fluorouracil (TPF) followed by chemoradiation with cisplatin. After one year, recurrence was observed, and she was treated with laryngopharyngectomy. After another year, recurrence was observed , and CPP was initiated. Further progression was noted shortly after completion of cycle 3. There are limited data supporting the use of regimens similar to CPP in advanced head and neck cancer. Further study is needed to determine the relative efficacy and safety of CPP compared with other regimens containing monoclonal antibodies targeting the epidermal growth factor receptor, taxanes, platinum agents, and/or fluorouracil.


2021 ◽  
Vol 10 (28) ◽  
pp. 2094-2098
Author(s):  
Ravisankar Thommanparambil Raveendran ◽  
Shehna Abdul Khader ◽  
Ajith Kumar Vilasini Raghavan ◽  
Jayaraman Madambath Balan ◽  
Krishnannair Lalithamma Jayakumar

BACKGROUND Concurrent chemotherapy is a well-established treatment modality for locally advanced head and neck cancer. The concept of concurrent chemotherapy and radiation was introduced in an attempt to improve the local control and possibly influence the survival because of the high rate of local and distant failures observed with the combination of surgery and postoperative radiation. The relevance of this study was to assess the efficacy of our treatment and patience compliance and also study the effect in patients treated with cisplatin based concurrent chemo radiotherapy in advanced head and neck cancer. METHODS The prospective study was conducted in the Department of Radiotherapy, Government Medical college, Thrissur, Kerala comprising the newly diagnosed patients with locally advanced head & neck cancers over one year. Conventional radiotherapy with a dose of 66 Gy in 33 fractions over 6.5 weeks was given concurrently with Inj cisplatin 100 mg / 2 IV every 3 weeks and periodically followed up for one year. RESULTS This study revealed that complete response rate was higher in 61 – 70 year age group compared to lower age groups. Complete response cases were slightly higher in T1 disease compared to higher stages. Regarding nodal status, complete response and DFS were more in N0 tumours and worst in N3 tumours. It was found that complete response rates were slightly higher in stage III than stage IV. Comparing the grade of the tumour, complete response cases were slightly higher in WD and MD compared to PD. Complete response rate and disease free survival (DFS) were slightly higher in cases who had more than two chemotherapy cycles compared to one cycle. CONCLUSIONS Concurrent chemo radiation was not well tolerated in our study group. Only 23.5 % patients were able to complete the planned treatment. The positive side was that complete response was found in about 79.4 % of study patients & DFS at one year was 80 %. KEY WORDS Concurrent Chemo Radiation, Head and Neck Cancer, Cisplatin


2020 ◽  
Vol 106 (6) ◽  
pp. NP23-NP28
Author(s):  
Alessandro Guidi ◽  
Martina Violati ◽  
Miriam Blasi ◽  
Elettra Ferrari ◽  
Andrea Luciani ◽  
...  

Introduction: Head and neck cancer represents a variety of tumors involving different organs in the cervical district, burdened by poor prognosis when diagnosed in an advanced stage. Immunotherapy with both anti-PD-1 nivolumab and pembrolizumab has the aim of increasing overall survival for patients with this malignancy. We report the first case of immune-related encephalitis caused by nivolumab in this setting of disease and present a brief review of the literature. Case description: A 60-year-old woman had been treated with concomitant chemoradiotherapy for a locally advanced human papillomavirus–negative squamous cell carcinoma of the tonsil. After local recurrence, she was treated with platinum-based first-line chemotherapy, followed by nivolumab at further progression within 6 months. Nivolumab was administered for 19 weeks, then discontinued due to the occurrence of immune-related hypothyroidism and grade 2 diarrhea. A month after the onset of the endocrinopathy, the patient also developed steroid-responsive encephalitis, considered as a consequence of anti-PD-1 therapy. One year after discontinuation of immunotherapy, toxicities have resolved and the patient is maintaining a complete radiologic response. Conclusions: Immunotherapy is a relatively new and promising therapy in the field of oncology. Its mechanism of action, which aims to stimulate the immune system against cancer cells, is not comparable to systemic and cytotoxic chemotherapy, which directly attacks and destroys malignant cells. Despite these differences, immunotherapy is not to be considered free from side effects, sometimes life-threatening.


Sign in / Sign up

Export Citation Format

Share Document